MENU
+Compare
CRIS
Stock ticker: NASDAQ
AS OF
Jun 25, 04:59 PM (EDT)
Price
$2.14
Change
-$0.05 (-2.28%)
Capitalization
22.7M

CRIS stock forecast, quote, news & analysis

Curis Inc is a biotechnology company that develops and commercializes drugs and therapies in the immuno-oncology and precision oncology therapeutic areas... Show more

Industry: #Biotechnology
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
Interact to see
Advertisement
A.I.Advisor
a Summary for CRIS with price predictions
Jun 24, 2025

Aroon Indicator for CRIS shows an upward move is likely

CRIS's Aroon Indicator triggered a bullish signal on June 23, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 108 similar instances where the Aroon Indicator showed a similar pattern. In of the 108 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

CRIS moved above its 50-day moving average on May 23, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in of 223 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for CRIS moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 16 similar instances where the indicator moved out of overbought territory. In of the 16 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on June 18, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on CRIS as a result. In of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for CRIS turned negative on June 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 31 similar instances when the indicator turned negative. In of the 31 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

CRIS broke above its upper Bollinger Band on June 11, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.099) is normal, around the industry mean (16.515). P/E Ratio (0.000) is within average values for comparable stocks, (59.269). CRIS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (1.365) is also within normal values, averaging (253.659).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. CRIS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.34B. The market cap for tickers in the group ranges from 151 to 312.97B. NONOF holds the highest valuation in this group at 312.97B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 2%. For the same Industry, the average monthly price growth was 32%, and the average quarterly price growth was 17%. INNMF experienced the highest price growth at 220%, while ICU experienced the biggest fall at -63%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -31%. For the same stocks of the Industry, the average monthly volume growth was 29% and the average quarterly volume growth was 75%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 62
SMR Rating: 100
Profit Risk Rating: 95
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
CRIS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a drug company

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
128 Spring Street
Phone
+1 617 503-6500
Employees
49
Web
https://www.curis.com